 CAMBRIDGE, Mass., Feb. 09, 2021 GLOBE NEWSWIRE -- Vor Biopharma Nasdaq: VOR, a cell therapy company pioneering engineered hematopoietic stem cell eHSC therapies combined with targeted therapies for the treatment of cancer, today announced the closing of its previously announced initial public offering of 9,828,017 shares of its common stock, plus an additional 1,474,202 shares sold pursuant to the full option exercised by the underwriters, at a price to the public of 18.00 per share. The aggregate gross proceeds to Vor from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Vor, were approximately 203.4 million. The shares began trading on the Nasdaq Global Market on Friday, February 5, 2021 under the ticker symbol VOR. 